EDITOR'S NOTE
All-Star Journal Club
Neil Love, MD

TOPICS

Section 1: Bevacizumab Plus Chemotherapy as First-Line Therapy of Metastatic Breast Cancer
- Select publications
Section 2: Rationale for Combining Bevacizumab and Hormone Therapy
- Select publications
Section 3: Utility of the Oncotype DX™ Assay in Predicting Benefit of Adjuvant Chemotherapy
- Select publications
Section 4: Use of the Oncotype DX Assay in Clinical Practice
- Select publications
Section 5: Optimizing Adjuvant Chemotherapy
- Select publications
Section 6: Cardiac Toxicity Associated with Anthracycline-Based Chemotherapy (Nonanthracycline Alternatives)
- Select publications
Section 7: Trastuzumab as Adjuvant Therapy for HER2-Positive Breast Cancer
- Select publications
Section 8: Treatment of HER2-Positive Metastatic Disease
- Select publications

PANEL MEMBERS

G Thomas Budd, MD
Rowan T Chlebowski, MD, PhD
Charles E Geyer Jr, MD
William J Gradishar, MD
I Craig Henderson, MD
Clifford Hudis, MD
Joyce O’Shaughnessy, MD
Peter M Ravdin, MD, PhD
Hope S Rugo, MD
Debu Tripathy, MD
Antonio C Wolff, MD

Breast Cancer Update:
A CME Audio Series and Activity

Editor's Office | Faculty Disclosures

     
     

Terms and Conditions of Use and General Disclaimer
Copyright © 2006 Research To Practice. All Rights Reserved